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Last year Norman Hertzer, in his presidential 
address presented at the Forty-eighth Annual Meet- 
ing of the Society for Vascular Surgery) dealt with 
one aspect of outcome assessment in vascular sur- 
gery. He convincingly demonstrated that "results 
mean everything." Today I would like to expand on 
this theme and tackle the difficult question of how 
we should analyze and compare these results. My 
interest in outcomes assessment is a natural out- 
growth of more than 10 years of work on the 
SVS/ISCVS Ad Hoc Committee on Reporting 
Standards. 26 Now that reporting standards are 
available for most major categories of vascular 
disease, including recent revisions of the original 
arterial and venous standards, TM it is timely to 
consider extending their application beyond the use 
for which they were intended, the uniform report- 
ing of results in scientific journals, to a more 
systematic approach to comparing results, not only 
those of clinical investigations but those of prac- 
ticing vascular surgeons, as well. The results of 
therapy for vascular diseases have little meaning if 
presented in isolation, no matter how uniform and 
valid the criteria used for reporting them. They are 
intended to be compared with something, for ex- 
ample, the natural (untreated) history, best "medi- 
From the Department of Surgery, Vascular Surgery Section, 
University of Colorado Health Sciences Center. 
Presented at the Forty-third Scientific Meeting of the International 
Society for Cardiovascular Surgery, North American Chapter, 
New Orleans, La., June 13-14, 1995. 
Reprint requests: Robert B. Rutherford, MD, UCHSC Vascular 
Surgery, C-312, 4200 E. Ninth Ave., 5521, Denver, CO 80262. 
J VASe SURG 1996;23:5-17. 
Copyright 9 1996 by The Society for Vascular Surgery and 
International Society tbr Cardiovascular Surgery, North Ameri- 
can Chapter. 
0741-5214/96/$5.00 + 24/6/67840 
cal" therapy, another competitive treatment, or the 
same therapeutic approach carried out in a different 
manner. However, in comparing treatment out- 
comes in published reports, it is not always clear 
whether reported differences in outcome, even 
though statistically significant, are really due to the 
method of treatment, as claimed, or to other in- 
trinsic differences that may or may not be apparent 
from the study data, such as differences between the 
compared treatment groups in regard to disease or 
lesion severity, differences in the prevalence of risk 
factors or other factors that could significantly affect 
outcome, or differences in operator skill or ad- 
junctive therapy. So the proper comparison of 
outcomes goes much farther than standardized re- 
porting practices, as essential as these are. It requires 
not only reporting outcomes in a standard fashion 
but including comparable data on all factors known to 
affect those outcomes. Although this fact is implicit 
in our reporting standards, their value in comparing 
outcomes is limited, because we do not yet have a 
Systematic approach to using them for this purpose. 
A number of needs could be served by a 
standardized approach to outcome analysis in our 
field. It could help settle long-standing controversies 
over competitive therapeutic options and limit them 
in the future. It could allow us to more e:~pedi- 
tiously assess the merits of new therapies and 
technologies and to make valid comparisons of 
different treatments short of expensive randomized 
prospective trials. Accurate outcome comparisons 
would greatly aid in clinical decision making and, 
in combination with valid data on costs, help 
identify the most cost-effective treatment and justify 
its choice. Finally, a method of ensuring compa- 
rability of outcomes would make practice audits and 
surgical profiles more meaningful and reliable than 
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they now are. The last issue is of more than 
academic interest. All of us will be required to 
develop practice "profiles" in the future, if that 
is not already being done for us. The intent is 
that those with the best outcomes, that is, lowest 
mortalities and morbidities and shortest inten- 
sive care unit and hospital stays, would be re- 
warded in managed care systems. Unfortu- 
nately, because the best surgeons do not necessarily 
produce the best "bottom line" results, such com- 
parisons, unadjusted for case severity, may be 
quite unfair. Consider comparing carotid endarter- 
ectomy results from a practice heavily weighted with 
asymptomatic stenoses with those of a recognized 
expert to whom patients at high risk are fre- 
quently referred, or comparing the overall results 
of a predominantly limb salvage experience with 
one holding a liberal view towards operating on 
claudicators. Comparisons with raw outcome data 
are likely to be misleading, and this problem has 
already arisen in comparisons of the morbidities 
and mortalities of different surgeons and of differ- 
ent institutions carried out here 9 and abroad. 1~ 
It is clear from these experiences that in compar- 
ing surgical outcomes, adjustments need to be made 
for differences in case mix, but currently, we have 
no accepted method for doing this in vascular 
surgery. 
The goal of ensuring comparability of results 
may not be easy to achieve, but much can be done 
with what is already within our grasp, and it 
is better to consider what can be done than what 
cannot. We can  establish uniform criteria for suc- 
cess or failure, and we can  identify risk factors 
and other variables that significantly affect out- 
come and develop grading scales for them that 
will allow valid intergroup comparisons. In ad- 
dition, we can  set guidelines for acceptable clinical 
comparisons in addition to costly and lengthy 
prospective randomized trials. I will address 
some of these goals with specific recommenda- 
tions, but I wish to make it clear at the outset that 
these are only an initial attempt o see what can be 
done in extending our reporting standards to out- 
come assessment. It will be up to others, ideally 
members of our ad hoc committee on reporting 
standards as I step down as chairman, to reject this 
approach for something better or adopt its better 
elements and modify them as appropriate. Then, on 
the basis of prospective testing by clinical investi- 
gators in our ranks, they can further modify the 
system. My intent here is to demonstrate the po- 
tential value of this approach and catalyze needed 
effort is this area. 
GENERAL CONSIDERATIONS IN 
PROPOSING A METHOD FOR 
COMPARING VASCULAR 
SURGERY OUTCOMES 
Outcomes can be gauged by a number of 
parameters: ome reflecting success, others reflecting 
failure. Outcome assessment balances out these as 
benefits and risks, and these data form the basis for 
the risk/benefit analysis each of us should perform 
before advising our patients regarding vascular inter- 
ventions. Put in simpler terms, this can be expressed 
in an "outcome quation" where at any given point 
in time after a procedure, the percent of patients with 
successful outcome equals those with continuing 
treatment benefit minus those who have died or had 
significant permanent morbidity as a result of the 
procedure. Uniform ground rules for dealing with 
mortality and morbidity are a relatively simple 
matter; the greater problem lies in establishing 
uniform criteria for treatment benefit, that is, agree- 
ing on who is "improved." In general, for scientific 
investigations the more valid outcome measures that 
are reported, the better the perspective. This belief is 
reflected in our current reporting standards. How- 
ever, there is an advantage, particularly in outcomes 
comparisons, to selecting a single or unified index of 
treatment benefit. This practice is also helpful for 
simpler clinical practice comparisons, as in compar- 
ing the results of two or more treatments for the same 
condition or the results of two or more providers of 
the same treatment. This essential element in the 
outcome equation will be addressed first, before 
deaths and complications, and because the end points 
of success are not the same for different categories of 
vascular disease, each will be discussed separately. 
Having suggested appropriate nd points of success 
and failure, I will then turn to an even more 
challenging task, suggesting severity scoring schemes 
by which these end points, mortality and morbidity 
and successful outcome, can be more readily com- 
pared in regard to the major variables that affect 
these outcomes. In doing so I will illustrate the 
potential of this approach with common examples 
from each of the four major disease categories 
represented in our reporting standards (lower ex- 
tremity ischemia, aneurysms, cerebrovascular insuf- 
ficiency, and venous disease). No attempt is made 
to be all-inclusive and develop the approach in its 
entirety. 
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OUTCOME CRITERIA FOR THE 
TREATMENT OF LOWER 
EXTREMITY ISCHEMIA 
With lower extremity revascularization, the most 
commonly quoted outcome criteria is arterial pa- 
tency. To most vascular surgeons patency is "king." 
This feeling is understandable, because if standard- 
ized reporting practices 7 are followed, patency is a 
universally accepted, objective end point. But, al- 
though patency rates are now better defined and 
more accurately determined and their importance as 
criteria for assessing the outcome of interventional 
treatment for lower extremity ischemia in scientific 
publications is even more secure, they should not 
serve as the sole criterion of success. First, patency does 
not always equate with true success even when 
dealing with revascularizations for lower extremity 
arterial occlusive disease. For example, major ampu- 
tation may still be required for sepsis superimposed 
on extensive necrosis, even though a graft remains 
patent. In addition, a fully patent bypass graft, 
endarterectomy, or percutaneous endovascular p o- 
cedure may be associated with clinical or hemody- 
namic failure. The best known example of this 
possibility isa proximal bypass or balloon angioplasty 
performed in the face of significant distal runoff 
disease that fails to relieve claudication or salvage the 
limb. Finally, patency rates are misleading when used 
to evaluate procedures primarily applied to stenosed 
but patent segments uch as balloon angioplasty. 
Clearly implied is the need for clinical, hemodynamic, 
and anatomic assessment both before and after 
operation. 
This need is why the SVSflSCVS standards for 
reports dealing with lower limb ischemia 2 recom- 
mend a scale for gauging "improvement" that com- 
bines categoric improvement in clinical status (with 
the proposed clinical categories for chronic limb 
ischemia) with objective vidence of improvement, 
namely, a significant elevation in the ankle brachial 
index (ABI). In the revised version 7(shown in Table 
I) this scheme requires the healing of foot lesions and 
relief of pain in those with chronic critical ischemia, 
significant improvement in claudicators, and objec- 
tive evidence of hemodynamic mprovement. Fur- 
thermore because the level of ABI increase for 
hemodynamic success i the same as required to claim 
patency, any patient at the + 2 or + 3 levels of the 
scale can be counted as not only clinically and 
hemodynamically improved but likely patent as well. 
This level of success could be called the clinical and 
hemodynamic improvement rate, or "patency plus," and 
Table I. Criteria for reporting significant 
changes in clinical status 
+ 3 = Marked ly  improved: all ischemic symptoms gone and 
any foot lesions completely healed; ABI increased to more 
than 0.90 
+ 2 = Moderately improved: no open foot lesions; still symp- 
tomatic, but only with exercise, and improved at least one 
category*; ABI increased by more than 0.10 but not nor- 
malized 
+ 1 = Min ima l ly  improved: greater than 0.10 increase in ABI 
but no categoric improvement or vise verse (i.e.,'upward 
categoric shift without an increase in ABI of  more than 
0.10) 
0 = No change: no categoric shift and less than 0.10 change 
in ABI 
- 1 = Mi ld ly  worse: no categoric shift but ABI decreased 
more than 0.10, or downward categoric shift with ABI 
decrease less than 0.10 
- 2 = Moderately worse: one category worse or unexplained 
minor amputation 
- 3 = Marked ly  worse: more than one category worse or un- 
explained major amputation 
*Categories refer to clinical classification in original standards. 
it is clearly a more satisfactory end point of success 
than patency alone. 
However, although this clinical and hemody- 
namic improvement rate makes the best sole end 
point of success and can be applied to both claudi- 
cators and those with chronic critical ischemia, for 
publications in scientific journals additional perspec- 
tive is necessary and needs to be different for gauging 
the results of treatment for claudicators and for those 
with "chronic critical ischemia." Relief of claudica- 
tion is an obvious goal, but because these symptoms 
can be relieved by simply limiting the walking 
distance, something more is needed to claim success. 
Even if the revascularization f one limb is patent and 
a hemodynamic success, the patient is not benefited 
if he or she cannot ambulate significantly farther 
because of unmasked angina, claudication in the 
other leg, or some other complication of the proce- 
dure. Functional ability must be improved and can be 
assessed in a number of ways, 12 but to count as a 
success the activity level should be improved to the 
point that the patient is no longer disabled or impaired 
relative to his or her needs of daily living. To make this 
assessment objectively a questionnaire-based scale 
with community-related walking activities has been 
developed and tested for this 10urpose. is Such func- 
tional measures, or at least walking distance on a 
standardized treadmill protocol, or both, should be 
used in clinical investigations evaluating the treat- 
ment of patients with claudication. For those with 
chronic critical ischemia and for those with acute 
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Table II. Final clinical outcome 
after operation for venous insufficiency 
+ 3 = Asymptomatic; improved at least one clinical class; 
improvement of VRT and AVP to normal or at least + 5 
seconds, and - 10 tort, respectively 
+ 2 = Moderate improvement; continuing mild symptoms 
with same clinical and vascular laboratory improvement as
in +3 
+ 1 = Mild improvement; improvement in either clinical 
class or vascular laboratory tests, but not both 
0 = Unchanged clinical or by laboratory tests 
- i = Mild worsening; worsening of either clinical outcome 
by one category or vascular laboratory tests 
-2  = Significant worsening; both clinical and vascular 
laboratory worsening 
-3  = Markedly worsening; same as -2  accompanied by ei- 
ther new or worsening ankle claudication 
VRT, Venous refill time; AVP, ambulatory venous pressure. 
critical ischemia beyond the "viable" category (level 
I), the "limb salvage rate" is the best indicator of 
success, i f  the recommended definitions and rules in our 
reporting standards 2 are strictly adhered to. 
OUTCOME CRITERIA FOR OTHER 
VASCULAR CATEGORIES 
The value of the patency rate is of much less 
importance when the treatment of other categories of 
vascular disease is evaluated rather than that of 
extremity arterial occlusive disease. What good is 
restoring patency of a thrombosed iliofemoral venous 
segment by thrombolysis or thrombectomy, if in- 
competent valves in or distal to these patent segments 
still produce significant postthrombotic sequelae? Of  
what use are patency rates after aortic aneurysm 
repair, where high flow through large-caliber grafts 
placed in the relative absence of associated occlusive 
disease almost guarantees patency? What value are 
patency rates for endarterectomy of the high-flow, 
low-resistance carotid bifurcation, especially when 
that segment is patent o begin with? The reporting 
standards for venous, 4 aneurysmal, 5 and cerebrovas- 
cular 3 diseases adequately identify and detail the 
appropriate outcome criteria for reports in scientific 
journals and will not be reiterated here. Only the 
most important indexes of success for each will be 
addressed. 
For venous procedures intended to prevent or 
ameliorate chronic venous insufficiency, a scale much 
like that recommended for gauging "improvement" 
after revascularization procedures for peripheral ar- 
terial occlusive disease has been recommended and 
retained in the original 4 and revised 8 venous stan- 
dards (Table II). This improvement score requires 
categoric linical improvement of at least one grade 
plus objective vidence of improvement on noninva- 
sive physiologic testing, and, as with the arterial scale, 
a + 2 or + 3 level of  improvement is recommended 
as the best index of success. Clinical improvement 
alone, for example, the lack of new venous ulcers 
during interval follow-up, is an inadequate outcome 
measure. Repeated observations over the years have 
established that the additional care associated with 
postoperative follow-up, for example, new elastic 
support stockings and a greater opportunity for rest 
and elevation, can by itself produce significant 
improvement at least for the short term. A scheme 
that adjusts for this variable will be described later, 
but the principle of requiring categoric linical plus 
objective hemodynamic improvement is strongly 
endorsed here. 
For aortic aneurysms patency is a relatively minor 
consideration in judging outcome. Freedom from 
recurrent aneurysm at the anastomoses and the 
immediately adjacent arterial segment and freedom 
from major complications of the graft or repair (i.e., 
graft occlusion, graft infection, aortoenteric fistulas, 
prosthetic "fabric failure") should be included in any 
definition of success applied to elective operations for 
abdominal aortic aneurysm (AAA). However, be- 
cause these operations are primarily performed to 
prevent death of ruptured AAA, survival must be an 
additional criterion. Thus survival without recurrent 
aneurysm and major procedure-related complications 
should be the combined end point of success for 
elective AAA repair, one that could be referred to as 
the complication free survival rate. The same recom- 
mendation applies to operations for ruptured AAA, 
but here the emphasis on survival will prevail in most 
short-term reports. 
For operations on extracranial arteries, of which 
carotid endarterectomy (CEA) is the prototype, the 
criteria for success are now clearer. The previous 
controversy over whether a patient with a high-grade 
asymptomatic carotid artery stenosis can be counted 
as "improved" by carotid endarterectomy is now 
obsolete. Currently, freedom from "stroke" is the 
generally accepted primary end point of treatment, 
but even that requires refinement. Considerable 
sentiment exists against including transient ischemic 
attacks (TIAs) as a postoperative failure. Many 
neurologists who in the past would refer patients for 
carotid endarterectomy only after a TIA do not 
consider TIA a valid end point in trials in which CEA 
is compared with the natural or medically treated 
history of carotid stenosis. In fact, the recent Veterans 
Administration Hospitals cooperative trial on asymp- 
tomatic carotid stenosis ~4 was criticized because it 
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could not show a statistically significant difference in 
favor of CEA without including TIAs. l~ But al- 
though it is only fair that if TIA is not counted as a 
thilure of medical therapy it should not be included as 
a failure ofsurgicaltherapy, it is also inappropriate to 
count as "improved" those patients with TIAs after 
operation, if this was their indication for operation 
in the first place, or if they had no symptoms before 
endarterectomy. Under our current cerebrovascular 
reporting standards 3 all such ischemic events are 
considered strokes, be they "brief, .... temporary," or 
"permanent." By that definition freedom from 
"stroke" can be considered as a primary index of 
success in judging the results of carotid endarterec- 
tomy. Although carotid endarterectomy may offer 
some protection against contralateral stroke, strokes 
in other territories than the ipsilateral carotid should 
not be counted against carotid endarterectomy, nor 
should asymptomatic carotid restenosis, o long as it 
does not require reoperation. Counting all strokes when 
comparing endarterectomy with medical therapy has 
some logic to it, but it weighs the outcome data 
against CEA. As long as both groups receive "best 
medical therapy," this procedure is not necessary. 
Although freedom from stroke as defined previously 
or reoperation to prevent stroke can be combined to 
serve as primary end points of success, a more 
detailed presentation of results is required for reports 
in scientific journals, as recommended in the current 
standards? 
TREATMENT FA ILURE:  REPORTING 
DEATHS AND COMPL ICAT IONS 
Death would seem to be an absolute and defini- 
tive end point. Nevertheless, even this obvious 
outcome requires elaboration in regard to reporting 
practices. Beware of reports citing "procedure-related 
mortality," for it is not only subjectively determined 
bu~ may reflect a bias. "Hospital death" is another 
unsatisfactory end point, particularly in these days 
when the pressures for early discharge are almost 
irresistible. Certainly death from myocardial infarc- 
tion on the day after early discharge after CEA should 
count against he procedure. Even deaths occurring 
within 30 days of the procedure, the traditional 
method of calculating postoperative mortality and 
the least subject o bias, may not tell the entire story. 
For example, an in-hospital death from multiple 
organ failure occurring 5 weeks after repair of a 
ruptured AAA would not be counted. However, this 
at least is an equitable, objective, and practical end 
point, and for that reason and the fact that it is more 
practical for retrospective practice audits, it is recom- 
mended for simpler clinical comparisons. The com- 
bination of any death within 30 days of the procedure 
and any death relatable to complications developing 
with 30 days of the procedure is more inclusive and 
is recommended for scientific publications. 
All major complications should be listed in scientific 
reports and be included in the outcome analysis of 
any vascular intervention. Major complications in- 
clude any that result in death or permantnt disability, 
require reoperation or invasive intervention to pre- 
vent or treat failure of the procedure itself (e. g., 
thrombectomy or thrombolysis), significantly delay 
hospital discharge, or result in prolonged pain or 
disability beyond the normal recovery period. In this 
context "permanently disabled" implies inability to 
return to preoperative activity levels without signif- 
icant limitations or requirement of use of assistance 
or artificial aids over the long term. Reporting the 
rates of postoperative death and permanent disability 
and the major complication rate will suffice for most 
reports, but for those in which a claim is made that 
one method of treatment is safer than another, 
additional information is required. In a chapter 
entitled "Suggested standards for reporting compli- 
cations of vascular surgery, "16 I developed both a 
disability and a complication severity grading scale 
for this purpose. The latter scale can be used to 
produce a complication severity score, which may be 
useful in some outcome comparisons. In this chapter 
the list of vascular complications appended to the 
original standards 2 is expanded and graded from 1 to 
3 (mild, moderate, and severe) with defined criteria. 
ENSURING COMPARABIL ITY  
OF OUTCOMES 
Having discussed standard criteria for reporting 
success and failure, let me turn to the more difficult 
task of how to ensure comparability of outcomes. 
The ideal method of comparison is the prospective, 
controlled, randomized trial based on valid premises 
and sound protocol, but although the need and 
guidelines for such studies are well established,17 they 
are often prohibitively expensive in terms of time, 
effort, and cost. Some trials might even be considered 
unethical depending on the perceived efficacy of the 
therapy. In addition, they are uslially not.applicable 
to evolving new technologies or therapies. Therefore 
reasonable ground rules need to be established for 
valid comparisons of different treatment strategies 
short of prospective, randomized trials. 
A wide variety of types of clinical evaluations exist 
and range from unacceptable to acceptable in regard 
to their validity in outcomes comparisons. Retrospec- 
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tive comparison with older "historic" control groups is 
intrinsically flawed, because ven if it is done without 
bias, the passage of time introduces numerous 
nonspecific improvements that benefit the more 
recent experience. Selective comparison with histori- 
cal control groups is a well-known ploy for making a 
new procedure look better than previous methods of 
treatment. It is intended to deceive, and unfortu- 
nately it still works on the unsuspecting. Comparison 
with contemporary external control groups with reports 
from other experiences i somewhat better than the 
selective comparison, but only to the extent hat the 
selection of these other reports is unbiased, and that 
is difficult to determine. 
Comparison with contemporary internal control 
groups is better yet and obviously better than com- 
parison with the experiences from other institutions, 
but even these comparisons must be well matched in 
terms of risk factors and any other factors known or 
suspected toaffect "outcome. The latter factor is the key to 
anygood clinical comparison. A good match may occur 
fortuitously, and this may be demonstrated by 
showing no significant differences between the 
groups being compared, in patient characteristics 
and the other major factors affecting outcome. If  the 
groups are not comparable, they may be matched 
retrospectively b  characterizing the groups in regard 
to the major factors affecting outcome and then 
pairing cases in the smaller treatment group with 
cases from the larger group. However, this retrospec- 
tive matching must be done by someone blinded to 
outcome. The validity of such "matched comparisons" 
should always be demonstrated by a lack of statisti- 
cally significant differences in factors affecting out- 
come. This rule also applies to prospective compari- 
sons, whether andomized or not. 
These balanced methods of comparison, from 
randomized prospective trials to well-matched retro- 
spective comparisons with contemporary internal 
control groups, are scientifically sound and both 
necessary and appropriate for scientific reports com- 
paring major therapeutic options. But what is accept- 
able, short of these, for comparison of differing 
clinical practices? How can practicing vascular sur- 
geons compare treatment A versus treatment B in 
their own experiences, or how can health care 
administrators compare the results of two surgeons 
or two groups of surgeons performing the same 
procedure? Such comparisons are not likely to be 
valid without taking into consideration intrinsic 
differences between the patients treated. A means of 
adjusting for or scoring case severity is needed. If  we 
could develop a severity scoring system for each major 
category of vascular disease, it would not only have 
value in providing better perspective for unmatched 
clinical comparisons, but it should also allow the 
validity of matched comparisons and trials to be 
tested. For this purpose I would like to propose an 
approach that would use, wherever possible, grades 
and scales that already exist in our reporting stan- 
dards. 
A SCHEME FOR USING CURRENT 
STANDARDS IN  SEVERITY SCORING TO 
FACIL ITATE OUTCOMES COMPARISONS 
IN VASCULAR SURGERY 
To be useful to clinicians and researchers, a
severity scoring system for comparing outcomes 
must be simple or able to be reduced to simple terms. 
Ideally it should also be specific for the treatment of 
vascular diseases, apply to criteria for successful 
outcome, not just mortality and morbidity, and use 
preoperative data. Existing severity scoring systems 
do not have these characteristics. The more complex 
severity scoring systems, like Apache II, some of the 
trauma severity scales, and even POSSUM, ~8 are hard 
for those not regularly involved in clinical research to 
embrace, let alone use. The simplest and most 
practical grading system in medicine seems to be the 
common four-level, 0 to 3 scale. Most of us are 
familiar and comfortable with the simple categories 
of 0-none, 1-mild, 2-moderate, and 3-severe. Fortu- 
itously but not coincidentally, this approach has 
already been applied to most of the risk factors 
featured in the current SVS/ISCVS reporting stan- 
dards. In addition to these risk factors, operative 
complications, the clinical categories of both acute 
and chronic limb ischemia and of chronic venous 
insufficiency, and several other grades or classifica- 
tions in our reporting standards are compatible with 
or adaptable to this simple four-level scale. By using 
these and a few additional similar grading schemes, 
group severity scores can be calculated for each 
pertinent factor, that is, each variable that signifi- 
candy affects outcome. For scientific reports multiple 
outcome-affecting factors (OAF's) can be scored in this 
manner, but for simpler clinical comparisons only the 
most dominant factor affecting outcome, that is, the 
clinical class or category, or at most a combination of 
two or three codominant factors, should be used. 
Ideally scientific reports would grade all significant 
outcome factors for which data were available and 
not only report a mean severity score for each risk 
factor but calculate an overall disease severity score 
for each treatment group or surgical experience by 
combining and averaging severity scores for all 
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OAFs. In this way all scores would range from 0 to 
3. Ultimately it may prove better to eliminate some 
risk factors or differentially weight others, but that is 
for future investigations. At the outset, using all the 
factors that are known or generally presumed toaffect 
outcome for scientific reports and selecting the most 
dominant factor(s) for simpler clinical comparisons 
should suffice. 
Let me present some examples to show the 
potential of this approach. Because different factors 
affect the two major elements of the outcome 
equation, success (significant treatment benefit) and 
failure (operative mortality and major procedure- 
related complications), these will be presented sepa- 
rately, and because procedure-related complications 
might be scored by a single unified scheme that could 
be applied to the mortality/morbidity risk of all 
vascular operations, it will be addressed first. 
COMPARING THE SEVERITY OF THE 
MORTALITY AND MORBIDITY RISK OF 
VASCULAR INTERVENTIONS 
Mortality rates dominate outcome comparisons. 
Much has been done outside of our field in an attempt 
to predict or adjust risk for differences in mortality, 
and in some instances morbidity as well. Risk- 
adjustment analysis has been attempted with some 
success in comparing results from different institu- 
tions in other areas of specialized care (cardiac sur- 
gery, 19'2~ severe head injury, 21'22 and intensive 
care. 23"24) Of the various approaches tried, the best, in 
my view, appears to be POSSUM, a Physiologic and 
O__perative Severity Score for the EnUmeration of 
Mortality and Morbidity, which has been specifically 
developed and tested for this purpose.Is t appears to 
be best suited to general surgery audit, 2s,26 but it has 
even been applied to a vascular surgery audit in the 
United Kingdoms In a 1-year prospective audit of 
surgeons' performances, Copeland et al.2s showed 
that wide ranges of mortality (1.0% to 4.9%) and 
morbidity (5.3% to 12.6%) were essentially nullified 
when the results were risk-adjusted with the 
POSSUM system. The system has been favorably 
compared with Apache II, 26 but even though simpler 
than Apache II, it still requires the collection of con- 
siderable data (12 patient physiologic parameters and 
6 aspects of the operative procedure), much of which 
is not specific for or relevant to vascular surgery. In 
addition, some of the data can be entered only after 
operation, for example, intraoperative blood loss, 
which could reflect poor surgical technique rather 
than intrinsic procedure severity. The advantage to 
using only preoperative data is that with prospective 
testing, such a system could potentially be used to 
predict operative risk and allow more discriminating 
risk/benefit analysis to be applied to individual pa- 
tients. Whether POSSUM could be modified and 
made more applicable to vascular surgery remains to 
be seen, but at least it has demonstrated the potential 
value of adjusting for differences in case-mix in com- 
paring results. However, in my view we would do 
better to try to develop asimpler system, and one that 
is specific for vascular surgery. 
Cardiac deaths, related primarily to coronary 
artery disease, dominate the early and late mortality 
rate for elective vascular surgery, accounting for close 
to two thirds of deaths in those operated for 
atherosclerotic disease. Because of this difference 
between patients undergoing vascular surgical pro- 
cedures and the broader spectrum of patients under- 
going general procedures, it is conceivable that 
grading for cardiac risk alone might provide a simple 
severity scale for comparing clinical practices, at least 
in the western world, where arterial operations for 
atherosclerotic disease predominate. However, it 
would not be universally applicable, and it certainly 
would be of much less value in venous surgery. 
Nevertheless, cardiac risk deserves to be heavily 
weighted. 
A number of systems have been developed for 
assessing cardiac risk. How applicable are they? 
Goldman's original index, 29 designed to apply to the 
broad spectrum of noncardiac operations, has not 
correlated well with cardiac risk in patients undergo- 
ing vascular surgical procedures, presumably because 
their sedentary lifestyle masks some of the clinical 
evidences of coronary artery disease. At least seven 
clinical scoring systems have been developed for 
determining cardiac risk, but in a study of 125 closely 
monitored patients undergoing vascular surgical 
procedures, Lette et al.30 found that of these and 18 
individual clinical parameters, only diabetes and 
Detsky score (not Detsky class) correlated with 
cardiac morbidity and death. Eagle's five clinical 
"markers" (age >70 years, diabetes, history or 
Q-wave evidence of previous myocardial infarction, 
previous congestive failure, history of angina pecto- 
ris) have proved useful in identifying patients at high 
risk but have served mainly to select patients for 
special noninvasive cardiac screening tests, like the 
dipyridamole-thallium scan. 31,32 However, our re- 
vised standards cardiac risk scale 7not only includes 
most of these markers but has been modified to 
include the results of cardiac screening tests, such as 
the dipyridamole-thallium scan, Holter monitor, and 
ejection fraction. Why not try them? 
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Table III. Patient risk score (part 
of scheme for comparing 
mortality/morbidity risk) 
Risk factor ~ 







Divide total by 10 for a 0-3 scale 
*All risk factors are scored according to SVS/ISCVS standards 7 
except age (see text). 
Although the risk of adverse cardiac events may 
correlate better with operative mortality after a major 
vascular procedure than any other single risk factor, 
some other variables should be considered if a 
broadly applicable severity scoring system is to be 
developed. Pulmonary and renal disease certainly 
have to be included, particularly in those patients 
undergoing major vascular surgical procedures (e. g., 
carried out within the chest or abdomen with aortic 
cross-clamping or significant blood loss). Other risk 
factors that warrant consideration are diabetes, hy- 
pertension, and age. With these in mind, a simple 
severity scoring scheme for patient risk factors is 
offered. As shown in Table III, it uses cardiac,* 
pulmonary, * and renal* risk factors as the major 
components and diabetes,* hypertension,* and age* 
(0 = <55 years, 1 = 55 to 69 years, 2 = 70 to 79 
years, and 3 = > 80 years) as minor components. In
this scheme, in recognition of the dominant role 
cardiac risk plays in both early and late mortality, the 
cardiac risk score is given a triple weighting, the 
pulmonary and renal scores are doubled, and the 
three "minor" components are singly weighted. The 
total is divided by 10 to give a patient risk score for 
correlation with operative mortality with a 0 to 3 
scale. The proposed scheme has the advantage, aswill 
most of the others uggested, of being immediately 
usable by anyone whose vascular egistry data are 
graded with SVS/ISCVS standards. 
However, although mortality and morbidity cor- 
relate with patient risk factors, they also significantly 
relate to procedural difficulty, which in this context 
refers to the physiologic stresses on the patient, not 
the technical challenge to the surgeon. In recognition 
of this, POSSUM 18 combines 12 patient playsiologic 
parameters with six details of the operative procedure 
*From revised SVS/ISCVS standards. 7 
in grading risk for operative mortality and morbidity. 
But, considering the problems with POSSUM pre- 
viously described, a simpler and better approach for 
vascular surgeons might be to develop a procedural 
risk score that is operation-specific. It could be used 
independently and combined with the patient factor 
risk score to gauge the overall risk of mortality and 
mortality after a vascular surgical procedure. 
A simple procedure severity score is offered in 
Table IV. It is based on the recognition that, 
relatively speaking, peripheral, extracavitary proce- 
dures (e.g., extremity, cervical, and subcutaneous 
bypasses) usually create only mild ( = 1) physiologic 
disturbances, whereas uncomplicated transabdomi- 
nal or transthoracic procedures inwhich no suprare- 
nal aortic clamping is performed present amoderate 
(=2) stress, and major thoracic, abdominal, or 
thoracoabdominal revascularizations requiring pro- 
longed supraaortic cross-clamping inflict the severest 
(= 3) physiologic hallenge. Venous operations of 
similar scope and location produce roughly equiva- 
lent stresses. These and other operations can be fitted 
in at equivalent levels within this framework. Severity 
is upgraded one level for emergency operation, 
predictable major blood loss ( > 4 U) on a maximum 
surgical blood-ordering scale (MSBOS33), or an 
additional revascularization, forexample, a concomi- 
tant distal or visceral bypass. This approach as the 
advantage that it can be used immediately and 
directly applied to practice audits using CPT codes. 
SEVERITY SCORING FOR COMPARING 
SUCCESSFUL OUTCOMES 
Finally, let me turn to the application of 
SVSflSCVS standards to severity scoring schemes 
for comparing successful outcome rates after thera- 
peutic interventions for vascular diseases. Whereas 
many of the OAFs are the same for each of the major 
categories of vascular disease, enough are substan- 
tially different. Therefore a common example will be 
presented in each of the four major categories. In each 
instance the factors used in severity scoring are 
intended to correlate with the primary criteria for 
successful outcome presented earlier. More complex 
interventions have received more detailed treatment 
than others. The list of factors applicable 63 disease 
severity scoring in each of the major categories i
summarized in Table V. 
Severity scale for comparing outcomes of 
treatment for chronic limb ischemia. For the 
outcome of procedures for chronic limb ischemia, the 
most practical single index for simple clinical com- 
parisons is clinical class, as adopted from the original 
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Table IV. Procedural risk score (part of scheme for comparing mortality/morbidity risk) 
Procedure risk Prototype Examples 
0 = Negligible 
1 = Mild 
2 = Moderate 
3 = Severe 
Superficial, local procedure 
Peripheral, cervical, or subcutane- 
()us bypass 
Uncomplicated abdominal or tho- 
racic bypass (without suprarenal 
clamping) 
Thoracic or abdominal revascular- 
ization (with prolonged supra- 
renal clamping) 
Saphenous ligation, temporal artery biopsy, wrist fistula 
Infrainguinal bypass, infraclavicular bypass, carotid endarterec- 
tomy, cervical bypass, extraanatomic bypass, sympathectomy, 
profundaplasty, peripheral venous valvuloplasty 
Simple AAA repair, aortoinnominate bypass, emergency trans- 
femoral thromboembolectomy, retrograde aortomesenteric or 
renal bypass, Warren shunt 
Thoracoabdominal aneurysm repair, complicated AAA repair 9 
(e.g., horseshoe kidney), repair of ruptured AAA, suprarenal 
endarterectomy, antegrade bypass for visceral ischemia, emer- 
gency portacaval shunt 
Table V. Severity scoring for comparing successful treatment outcomes 
Category Primary factor(s) Secondary factors Other variables 
Chronic limb ischemia Clinical class Diabetes Type of procedure 
Tobacco use Graft choice 
Runoff Level of anastomosis 
Acute limb ischemia 
Aneurysm (infrarenal AAA) 
Extracranial arterial (carotid 
Chronic venous disease 
Clinical class 
Patient mortality risk 
Patient mortality risk 
Technical difficulty 
Risk of recurrence 
Clinical status (modified CHAT) 
Clinical class 
Hypertension Severity of stenosis 
Ulceration grade Sex/Age 





Table VI. Severity scoring for operative treatment of chronic limb ischemia 
Patient factor 0 = None 1 Mild 2 = Moderate 3 = Severe 
Primary factor 
Clinical grade 




Other variables (infrainguinal) 
Level of anastomosis 
Graft ch~ce 
Type of procedure 
Asymptomatic Claudicator Rest pain Tissue loss 
1 2,3,4 5,6,7 8,9,10 
None Adult, diet Adult, insulin Juvenile 
None (> 10 yrs.) None (< 10 yr) Current, < 1 pk/day Current, > 1 pk/day 
Primary 
Popliteal above knee 
Greater saphenous 
To restore primary patency 
Popliteal below knee Infragenicular 
Other vein Prosthesis, biograft 
New bypass To restore secondary patency 
Fontaine classification and incorporated into the 
SVS/ISCVS standards: asymptomatic -- 0, claudica- 
tors = 1, rest pain = 2, and ulcers or gangrene = 3. 
This should be theprimary scoring factor. However, 
for scientific reports results should be stratified for 
each of these four levels and for some other variables 
pertinent to a particular operation's outcome. For 
example, factors that clearly affect outcome of 
infrainguinal bypass are level of anastomosis and 
choice of  graft. In addition to these, generic factors 
with a potentially significant effect on outcome can 
also be stratified and scored, namely, diabetes, 
tobacco use, and runoff, as shown in Table VI. 
Finally, reoperation for failure of  a previous revascu- 
larization clearly affects outcome. Again, in many 
reports these cases will not be mixed with primary 
procedures, but if they are, they can be graded as 
follows: primary operation = 0, operation to assist 
primary patency = 1, operation to restore secondary 
patency -- 2, and a so-called secondary revasculariza- 
tion procedure, which does not contribute towards 
secondary patency (e.g., an additional new by- 
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pass) = 3. Depending on the data on these factors 
available in each report and the extent of subgroup 
stratification in regard to these same variables, 
severity scores can be developed for comparing the 
results in each treatment subgroup by combining and 
averaging the scores of all the OAFs. In more 
complex analyses data can be stratified to focus on the 
effect of each of multiple variables, developing 
severity scores based on all subjacent variables. Then, 
moving upward and combining subgroups, the 
variables previously excluded can be progressively 
included in the severity scoring up to the point where 
an overall severity score can be calculated for the 
entire experience. At each level of comparison the 
resultant scores will all range from 0 to a maximum 
of 3, maintaining a constant frame of reference. This 
approach to severity scoring can potentially not only 
allow valid comparisons among treatment groups 
within the same experience but can ultimately allow 
comparisons with other reported experiences, as long 
as most of the same risk factors are similarly scored 
and reported. The latter capability is one of the major 
rewards of this approach, namely, uniformly report- 
ing all pertinent risk factors and grading them by a 
standardized severity scoring system. 
A severity scoring scheme for comparing the 
results of  AAA repair. The current SVS/ISCVS 
aneurysm reporting standards s do not offer a single 
classification system for categorizing abdominal aor- 
tic aneurysms but rather recommend that aneurysms 
be "classified with a combination of the following 
factors: (1) site, (2) origin, (3) histologic features, 
and (4) clinicopathologic features. To relate success- 
ful outcome of elective aortic aneurysm surgery (i.e., 
survival free of local recurrence or major graft/repair- 
related complications) to the severity of the under- 
lying disease, a severity scoring system must be 
created e novo. The following three major variables 
deserve inclusion: technical difficulty, risk of local 
recurrence, and patient factor mortality risk. The last 
variable has already been described. It is appropriate 
here not only because it gauges early mortality but 
also because many of the same factors determine late 
survival. 
For grading the technical difficulty of infrarenal 
AAA repair, the following scale might be applied. 
With a simple tube graft as a base of zero, one point 
is added for any of the following: need for a 
bifurcation graft, juxtarenal involvement requiring 
suprarenal clamping, and for "hostile" abdominal or 
other complicating disease. The last condition would 
include inflammatory aneurysm, horseshoe kidney, 
caval or renal vein anomaly, reimplantation of 
inferior mesenteric artery or accessory renal artery 
required, massive/morbid obesity, aortic reopera- 
tion, more than two previous abdominal opera- 
tions, ostomy stomas present, abdominal irradiation 
greater than 4000 rads, and occlusive disease of 
visceral or lower extremity arteries requiring a 
concomitant bypass or other revascularization pro- 
cedure. In the event of more than one form of 
complicating disease, one additional point could be 
added, but the total score is not to exceed three. 
To gauge the risk of local recurrence the extent of 
the aneurysmal disease and indicators of a possible 
intrinsic deficiency in arterial wall integrity should be 
taken into consideration. For this procedure it is sug- 
gested that a base value of 0 could be assigned to an 
aneurysm confined to the infrarenal aorta and i point 
be added for extension to involve the iliac arteries, 
ectasia of the suprarenal aorta, or one of the following 
clinical indicators of intrinsic arterial weakness: gen- 
eralized ectasia, popliteal, femoral or multiple other 
aneurysms, or a family history of AAA in a first- 
degree relative. The total should not exceed 3. 
Outcomes after emergency AAA repair fbr rupture 
could be compared by the same criteria, but ordi- 
narily repair of ruptured AAA is judged only in terms 
of operative mortality. For such simpler comparisons 
the cases should be graded on the basis of condition 
on arrival and response to resuscitation by the time of 
laparotomy, simply as 0 -- no hypotension (pain 
only, with contained rupture), 1 = transient hy- 
potension (< 90 mm Hg) but with blood pressure 
and urine output restored by resuscitation, 2 = in- 
complete response to resuscitation with persistent or 
recurrent hypotension, no restoration of urine out- 
put, or both, 3 = no/negligible response to resusci- 
tation, or continued eterioration. 
Severity scoring for comparing the results of  
operations on extracranial arteries. For carotid 
endarterectomy the prototype operation for cere- 
brovascular insufficiency, a modified version of the 
clinical status scale of the CHAT system, 3 should 
serve as the primary severity score for simpler clinical 
comparisons, namely, 0 = asymptomatic, 1 = brief 
stroke/TIA, 2 = temporary stroke/reversible isch- 
emic neurologic deficit, and 3 = permanent or 
changing (acute) stroke. For scientific reports addi- 
tional perspective is needed. 0 to 3 scales for patient 
factor mortality risk (see previous text), for severity of 
stenosis and degree of ulceration (from original 
standards3), and for occlusive disease located proxi- 
mally, distally, or collaterally in other extra- and 
intracranial arteries, as recommended previously by 
the author, 34 all can be used in severity scoring as 
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Table VII. Severity scoring for comparing outcome of treatment of carotid artery occlusive disease 
Patient factor 0 = None I = Mi ld 2 = Moderate 3 = Severe 
Primary factor 
Clinical status (type of Asymptomatic Brief (TIA) Temporary (RIND) Permanent or changing 
stroke-modified (acute) 
CHAT) 
Secondary risk factors 
Hyperlipidemia Normal Diet-controlled Medication-controlled Uncontrolled 
Tobacco use None ( < 10 yrs) None ( > 10 yr) Current, < 1 pk/day Current, > 1 pk/day 
Hypertension None Controlled, with 1 drug Controlled, with 2 drugs Requires > 2 drugs,. 
uncontrolled 
Age/gender ( + 1 if Male, > 65 yrs Male, 50-64 Male, < 50 yrs 
&male) 
Other variables 
% Stenosis 0%-19% 20%-59% 60%-79% 80%-99% 
Ulcer grade None < 2 mm depth, breadth > 2 mm depth, breadth Giant, multiple 
Collateral occlusive No significant ( > 60%) > 60% narrowing in con- > 60% in both contralat- A complete occlusion 
disease occlusive lesions in tralateral carotid or eral and vertebrobasilar in both pathways 
collateral pathways in basilar or both 
vertebrals 
appropriate for the particular eport. In addition, 
generic risk factors affecting late outcome could 
include sex, age, hyperlipemia, tobacco use, and 
hypertension. These are summarized in Table VII. 
Their application would follow the same principles 
laid down previously, that is, the factors affecting the 
outcome criteria being compared should be scored 
individually for group stratification and outcome 
comparison. Overall disease severity scores can be 
developed by combining and averaging as appro- 
priate. 
Severity scoring for comparing the results of 
treatment for chronic lower extremity venous 
disease. A severity scale is needed that would 
encompass all cases of chronic venous insufficiency, 
whether related to the posrthrombotic state, congeni- 
tal anomalies, or long-standing primary varicose 
veins. The three-level c inical classification system of 
the original standards 4 should continue to satisfy 
simpler clinical needs. A slightly more complex 
clinical classification has been proposed in the up- 
dated version, 8 with six rather than three levels. 
However, these can be easily converted to a roughly 
identical 0 to 3 scale (0 = 0, and classes I and 2 = 1, 
classes 3 and 4 -- 2, and classes 5 and 6 -- 3). Such 
a disease severity scale can be used for simpler clinical 
comparisons of the results of treatment of various 
forms of chronic venous insufficiency and could serve 
as the primary factor for severity scoring, but for 
scientific reports more discriminating criteria are 
obviously needed. However, developing a more 
comprehensive s verity scoring scheme for lower 
extremity venous disease isa challenge that has eluded 
many, including the author. The Clinical, Etiology, 
_Anatomy, and Pathophysiology (CEAP) classifica- 
tion system 3s developed by an international consen- 
sus group at the American Venous Forum in 1994 
may provide the basis for a more comprehensive 
severity grading system, or, similar to the CHAT 
system, 36 it may prove too cumbersome when used in 
its entirety and be keyed primarily on clinical class. 
Nevertheless the basic elements it represents should 
be considered for inclusion in some form in scientific 
reports. Converting it from a classification system 
into numeric grades for severity scoring would aid in 
gaining acceptance for the system, but to my 
knowledge this conversion has not been done. 
Next to clinical class in importance ispathophysi- 
ologic grading. Obviously, noninvasive t sting will be 
the ultimate key to grading the true severity of the 
physiologic abnormalities associated with lower ex- 
tremity venous disease, but at present we lack a 
method that gives a single measure bat  reliably 
correlates with ambulatory venous pressure. Lacking 
this measure, one can use "global" measures that will 
stratify limbs according to the severity of either 
valxnalar reflux or obstruction. Thus one could grade. 
patients from 0 to 3 according to whether they have 
by physiologic testing significant overall reflux (--2 
points) or significant outflow obstruction (--1 
point). Patients with both proximal obstruction and 
distal reflux would fall into the sevel'e category, with 
a score of 3. Photoplethysmography, impedance 
plethysmography, and air plethysmography give 
global measures of reflux and obstruction, but their 
considered lack of reliability and wide availability are 
current drawbacks. Duplex scanning is becoming 
increasingly useful in gauging segmental reflux and 
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Table VIII. Venous severity scoring scale based on segments involved with obstruction or reflux 
segmental involvement (score) 
Reflux Obstructed 
(1) Partial (thigh or cal 0 superficial veins 
(2) Complete (thigh and calf) saphenous 
(1) Perforators (single, one group) 
(2) Multiple perforators, more than one group 
(1) Calf veins, partial (tibial or muscular) 
(2) All calf veins (tibial and muscular) 
( 1 ) Popliteal vein 
(1) Superficial femoral vein 
( 1 ) Profunda temoris vein 
(1) Common femoral vein 
Maximum reflux score = 10 
(1/2) Saphenous vein alone 
(1) Saphenous vein in association with proximal DVT 
(1/2) Muscular veins 
(V2) Tibial veins 
(1/2) Popliteal vein 
(~/2) Superficial femoral vein 
(1/2) Profunda fcmoris vein 
(1/2) Common femoral vein 
(~/2) Iliac vein 
(1/2) IVC 
Maximum obstruction score = 5 
Normally, there are no iliac or caval valves. 
Table IX. Clinical severity classification 
of chronic venous disease (incorporating 
the effect of treatment/compliance with 
a program of elastic stockings and 
leg elevation) 
0-No signs or symptoms of venous disease 
1 -Telangiectasias, reticular veins, malleolar flare 
2 - Varicose veins 
3 -  Edema without significant stasis skin changes 
4 -Brawny edema with limited (noncircumferentiaI) stasis 
skin changes 
5-Advanced (circumferential) pigmentation, inflammation, 
or scarring 
6 -  Single occurrence of ulceration (healed or active, but 
healing) 
7-Mult iple/recurrent ulcers, or "never" healed ( > 1 yr) 
To the above levels the fbllowing "treatment modification" points 
are added in a sliding scale for a maximum score of 10: 
0 -No  compliance, untreated. 
+ 1 -Poor  compliance (only occasionMly wears elastic stockings, 
elevates legs). 
+ 2 -Fa i r  compliance (usually wears elastic stockings, but only 
ocasionally elevates legs). 
+ 3 -  Excellent compliance (always wears stockings, elevates legs 
multiple times daily). 
has obvious value in assessing venous reconstructive 
procedures, but it does not provide a useful objective 
measurement (in terms of numeric data) of either 
overall venous reflux or significant outflow obstruc- 
tion. However, the segmental information it does 
provide on reflux and obstruction could be converted 
into a numeric scoring scale that combines two of the 
remaining three elements of the CEAP System, 
anatomy and pathophysiology, with the use of a 
scheme similar to that shown in Table VIII. Again, 
this 10-point scoring system can be converted into a 
simpler 3-point scale, if desired, much as done 
previously for the SVS/ISCVS runoff score. 
An unsolved problem in gauging the severity of 
legs with chronic venous insufficiency on purely 
clinical grounds is that patients vary greatly in the 
degree to which they have been treated by and 
complied with a regimen combining properly fitting 
elastic stockings and frequent leg elevation. An 
ulcerated leg in a noncompliant patient may represent less 
severe intrinsic disease than brawny edema in a very 
compliant patient. For this reason I would suggest 
modifying the current clinical classification scheme to 
allow for the effects of conservative treatment and 
compliance. An example of how this might be 
accomplished is shown in Table IX. For the sake of 
uniformity this decimal scale can be converted into a 
3-point scale, in the same manner previously sug- 
gested. 
CONCLUSION 
As you can see, comparing outcomes is not a 
simple matter, but if we develop a good, readily 
usable approach to outcomes comparisons, one by 
which the results of our labors can be properly 
judged, the results are great. An important aspect of 
comparing outcomes that I have not addressed is 
accurately comparing costs. Comparing outcomes 
and costs goes hand in hand in providing the basis for 
cost-conscious, clinical decision making. In my view, 
good clinical research on these aspects of vascular 
surgery rank in importance with basic research and 
should be encouraged. 
I hope I have convinced you that comparing 
outcomes in vascular surgery requires auniform and 
practical system by which results can be risk-adjusted 
for intrinsic differences in disease severity and other 
variables that are likely to affect hose results. I have 
tried to make a start at this system by applying 
existing elements of our reporting standards. But it is 
just that, a beginning. I hope that some of you will 
use it, evaluate it, and modify and refine it. I offer 
assistance to those who want to work on this aspect 
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of vascular surgery, but future versions should be 
developed by those who are most likely to use and 
benefit from them. 
In closing, I would like to say that I will continue 
to cherish the honor of  representing you as your 
president and hope to be able to continue to work for 
some time in the future on your behalf. 
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